Blood tumor mutational burden (bTMB) from circulating tumor DNA (ctDNA) as a biomarker for both mutational status and tumor burden in non-small cell lung cancer (NSCLC)

被引：1
|
作者：
Davis, Andrew A. [1 ]
Galvez, Carlos [1 ]
Pan, Alan [1 ]
Mohindra, Nisha [1 ]
Villaflor, Victoria [1 ]
Chae, Young Kwang [1 ]
机构：
[1] Northwestern Univ, Chicago, IL 60611 USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-3644
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3644
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Spotlight on tumor mutational burden in patients with non-small cell lung carcinoma Preface
    Ilie, Marius
    Hofman, Paul
    TRANSLATIONAL LUNG CANCER RESEARCH, 2018, 7 (06) : 614 - 615
  • [22] Homologous Recombination Deficiency and Tumor Mutational Burden as Clinical Biomarkers for Non-Small Cell Lung Cancer
    Yip, James
    Lum, Christopher
    MODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 1351 - 1352
  • [23] Homologous Recombination Deficiency and Tumor Mutational Burden as Clinical Biomarkers for Non-Small Cell Lung Cancer
    Yip, James
    Lum, Christopher
    LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 1351 - 1352
  • [24] High Tumor Mutational Burden in Rare and Complex EGFR Mutant Non-Small Cell Lung Cancer
    Mo, A.
    Guha, C.
    Guha, U.
    Ohri, N.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : E255 - E256
  • [25] Tumor mutational burden in non-small cell lung cancer-the pathologist's point of view
    Penault-Llorca, Frederique
    Radosevic-Robin, Nina
    TRANSLATIONAL LUNG CANCER RESEARCH, 2018, 7 (06) : 716 - 721
  • [26] Clinical utility of tumor mutational burden in patients with non-small cell lung cancer treated with immunotherapy
    Hendriks, Lizza E.
    Rouleau, Etienne
    Besse, Benjamin
    TRANSLATIONAL LUNG CANCER RESEARCH, 2018, 7 (06) : 647 - 660
  • [27] Lung Cancer with a High Tumor Mutational Burden
    Diker, Omer
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (11): : 1093 - 1093
  • [28] Retrospective clinical analysis of circulating tumor DNA (ctDNA)-based molecular response (MR) and baseline blood-based tumor mutational burden (bTMB) for monitoring response in phase 3 trial of bintrafusp alfa vs. pembrolizumab treatment of non-small cell lung cancer (NSCLC)
    Feng, Zheng
    Machl, Andreas
    Wang, Danyi
    Overstreet, Brooke
    Yablonovitch, Arielle
    Scheuenpflug, Juergen
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [29] Ryanodine receptor (RYR) mutational status correlates with tumor mutational burden, age and smoking status and stratifies non-small cell lung cancer patient prognosis
    Wang, Yang
    Chen, Yun
    Zhang, Libin
    Xiong, Jian
    Xu, Lele
    Cheng, Changfu
    Xu, Zheyuan
    TRANSLATIONAL CANCER RESEARCH, 2022, 11 (07) : 2070 - +
  • [30] Clinical potential of circulating tumor DNA (ctDNA)-based molecular response (MR) and baseline blood-based tumor mutational burden (bTMB) for monitoring response to firstline (1L) chemoimmunotherapy in advanced squamous non-small cell lung cancer (sqNSCLC)
    Ciardiello, F.
    Feng, Z.
    Smith, N. R.
    Andric, Z. G.
    Shell, S.
    Yablonovitch, A.
    Guezel, G.
    Scheuenpflug, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1050 - S1051
12345